Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 5/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.30 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 2/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.30 |
| ▸ | ADAM9 | Q13443 | 1/20 | 0.30 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1015225 | 1.00 | REN (0.32) | RENUTS2RTSHRPDE4BBACE1 | |
| SCHEMBL1014019 | 0.93 | REN (0.35) | REN | |
| SCHEMBL1014018 | 0.93 | REN (0.35) | REN | |
| SCHEMBL1015531 | 0.93 | REN (0.35) | RENPDE4B | |
| SCHEMBL1017603 | 0.93 | REN (0.33) | RENPDE4B | |
| SCHEMBL1015530 | 0.93 | REN (0.35) | RENPDE4B | |
| SCHEMBL3885241 | 0.93 | REN (0.35) | RENPDE4B | |
| SCHEMBL1017601 | 0.93 | REN (0.33) | RENPDE4B | |
| SCHEMBL1014767 | 0.92 | REN (0.34) | RENPDE4B | |
| SCHEMBL1014766 | 0.92 | REN (0.34) | RENPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2271644-A1 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-7625893-B2 | Substituted 4-phenyl piperidines for use as renin inhibitors | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-01 | — | — | US | disclosed |
| WO-2009121914-A1 | SUBSTITUTED PIPERIDINES AS THERAPEUTIC COMPOUNDS | NOVARTIS AG (CH) | 2009-10-08 | — | — | WO | disclosed |
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | SPEEDEL EXPERIMENTA AG | 2009-04-02 | — | — | US | disclosed |
| EP-1934207-B1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2009-03-11 | — | — | EP | disclosed |
| EP-1934207-A1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | Speedel Experimenta AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1911758-A1 | Phenyl piperidine derivatives for use as renin inhibitors | Speedel Experimenta AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| WO-2008040764-A1 | SUBSTITUTED 4-PHENYL PIPERIDINES FOR USE AS RENIN INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2008-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088426-A1 | Substituted 4-Phenyl Piperidines for Use as Renin Inhibitors | REN, AGTR1, ACE | REN 1/4885UTS2R 169/4885TSHR 1904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.